

FOI REF: 21/044

18 February 2021

Tel: 0300 131 4500
Website: www.esht.nhs.uk

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- **Abatacept [Orencia]**
- **Adalimumab [Humira]**
- **Adalimumab Biosimilars**
- **Apremilast [Otezla]**
- **Baricitinib [Olumiant]**
- **Certolizumab [Cimzia]**
- **Etanercept [Enbrel]**
- **Etanercept Biosimilars**
- **Filgotinib [Jyseleca]**
- **Golimumab [Simponi]**
- **Infliximab [Remicade]**
- **Infliximab Biosimilars**
- **Ixekizumab [Taltz]**
- **Rituximab [MabThera]**
- **Rituximab Biosimilars**
- **Sarilumab [Kevzara]**
- **Secukinumab [Cosentyx]**
- **Tocilizumab [Ro Actemra]**
- **Tofacitinib [Xeljanz]**
- **Upadacitinib [Rinvoq]**
- **Ustekinumab [Stelara]**

As we are sure you will appreciate, the Trust is facing an unprecedented challenge in managing the coronavirus (COVID-19) pandemic. Our teams do not therefore have the capacity to respond to your freedom of information request during this extraordinary period and we apologise that we will not be able to respond. If you would still like the information please resubmit your request at the beginning of April.

Q2. Could you please provide the numbers of patients treated for Ankylosing Spondylitis in the last 3 months with the following drugs. (Please only include patients where there is radiographic damage on X-ray of sacroiliac joints)

- **Adalimumab [Humira]**
- **AdalimumabBiosimilars**
- **Certolizumab [Cimzia]**
- **Etanercept [Enbrel]**
- **EtanerceptBiosimilars**
- **Golimumab [Simponi]**
- **Infliximab [Remicade]**
- **Infliximab Biosimilars**
- **Ixekizumab [Taltz]**
- **Secukinumab [Cosentyx]**

[Please refer to question 1.](#)

Q3. Please could you provide the total number of patients treated with any biologic drug in the past 3 months who are diagnosed with the following:

- **Ankylosing spondylitis (i.e. with radiographic damage on X-ray of sacroiliac joints)**
- **Non-radiographic axial spondyloarthritis (i.e. without radiographic damage on X-ray of sacroiliac joints)**

[Please refer to question 1.](#)

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, please write to Lynette Wells, Director of Corporate Affairs, East Sussex Healthcare NHS Trust (lynette.wells2@nhs.net) quoting the above reference.

Yours faithfully

Linda Thornhill (Mrs)
Corporate Governance Manager
esh-tr.foi@nhs.net